Our Team
The scientists, engineers, and advisors developing and commercialising NanoPilot, Hone Bio's targeted LNP platform.
Leadership Team
Dr Ben Carter
CEO & Co-Founder
Ben co-founded Hone Bio to translate the NanoPilot targeted LNP platform from laboratory discovery into a commercially viable product. He holds a PhD in Cellular and Molecular Medicine from the University of Bristol and has been recognised with the Royal Society of Edinburgh Enterprise Fellowship, the Royal Academy of Engineering Shott Scale-Up Accelerator, and the Bioindustry Association Leadership Programme.
Prof. Adam Perriman
CSO & Co-Founder
Adam is Professor of Bioengineering at the University of Bristol and Australian National University, where his group develops hybrid biomolecular systems at the intersection of chemistry, synthetic biology, and materials science. His research has been recognised with the Wellcome Trust Frontiers Innovator award, the British Biophysical Society Young Investigator's Medal, and a UKRI Future Leaders Fellowship. As CSO, he provides technical governance ensuring scientific rigour across all Hone Bio development activities.
R&D Team
Dr Josh Bufton
Senior Protein Scientist & Co-Founder
Josh is the inventor of the core NanoPilot technology and uses his expertise in the design, engineering, and characterisation of the proteins at the core of Hone Bio's platform. He holds a PhD in Biochemistry from the University of Bristol and brings expertise spanning structural biology, protein biochemistry, and process development.
Dr Tom Green
Senior Research Scientist & Co-Founder
Tom is a co-founder of Hone Bio and a senior member of the R&D team. He holds a PhD in Cellular and Molecular Medicine from the University of Bristol, and leverages his deep protein design and synthetic biology experience to develop, build, and characterise NanoPilot constructs.
Dr Angharad Walters
Cell Biologist
Angharad manages Hone Bio's in vitro and in vivo validation programme, applying her expertise in oncology models, flow cytometry, and cell biology to characterise NanoPilot's targeting performance. She holds a PhD in Cancer and Genetics from Cardiff University and brings extensive laboratory experience from both academic and industry settings.
Board of Directors
The board includes the two executive founders alongside four non-executive directors who bring broad commercial, clinical, and investment experience.
Keith MacDonald
Chairperson
Keith brings extensive commercial leadership experience to his role as Chair of Hone Bio, having chaired Ziylo through its acquisition by Novo Nordisk and served as director and mentor to a range of companies — from early-stage start-ups to an AIM-listed software business with a market capitalisation exceeding £500 million. His broad experience across governance, commercialisation, and investor relations provides the Board with important strategic guidance.
Dr Harry Destecroix, MBE
Non-Executive Director
Harry is co-founder and Managing Partner of SCVC, a Bristol-based deep-tech venture firm. He previously founded Ziylo, a University of Bristol spinout developing glucose-sensing molecules, and led it as CEO through to its acquisition by Novo Nordisk in 2018 in a deal worth up to $800 million. His track record translating early-stage university science into significant commercial outcomes gives him a distinctive strategic perspective on Hone Bio's board.
Dr Andy Chapman
Non-Executive Director
Andy is CEO and co-founder of Carbometrics, a diagnostics company developing glucose-sensing technology. He was previously Chief Scientific Officer at Ziylo, where he helped develop the platform that led to the company's Novo Nordisk acquisition. He holds a PhD in Chemistry from the University of Bristol, an MBA from the Biotechnology Business Institute, and in 2020 received the Royal Society of Chemistry's Rising Star in Industry award.
Dr Mike Khan
Non-Executive Director
Mike is CEO of Argonaute Therapeutics and brings over 25 years of R&D and clinical leadership to Hone Bio's board. He was previously Chief Medical Officer at Silence Therapeutics, a clinical-stage RNA therapeutics company, where he oversaw clinical trials through to Phase II. He holds a PhD in Developmental Neurobiology from University College London and combines deep clinical expertise with specialist knowledge of nucleic acid therapeutics.